Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
VYNE Therapeutics (VYNE)
NASDAQ:VYNE
VYNE Therapeutics (VYNE) Stock Price & Analysis
1,803 Followers
VYNE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.67 - $8.73
Previous Close$2.3
Volume5.95K
Average Volume (3M)104.86K
Market Cap
$32.00M
Enterprise Value-$60.61M
Total Cash (Recent Filing)$93.25M
Total Debt (Recent Filing)$214.00K
Price to Earnings (P/E)-0.3
Beta0.95
Next Earnings
May 09, 2024EPS Estimate
-$0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.00
Shares Outstanding14,098,888
10 Day Avg. Volume92,302
30 Day Avg. Volume104,855
Standard Deviation0.24
R-Squared0.07
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)0.38
Price to Sales (P/S)70.94
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-142.95
Enterprise Value/Gross Profit-151.53
Enterprise Value/Ebitda2.19
Forecast
1Y Price Target
$5.88Price Target Upside159.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
VYNE Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VYNE FAQ
What was VYNE Therapeutics’s price range in the past 12 months?
VYNE Therapeutics lowest stock price was $1.67 and its highest was $8.73 in the past 12 months.
What is VYNE Therapeutics’s market cap?
Currently, no data Available
When is VYNE Therapeutics’s upcoming earnings report date?
VYNE Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 14 days.
How were VYNE Therapeutics’s earnings last quarter?
VYNE Therapeutics released its earnings results on Feb 29, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.5 by $0.32.
Is VYNE Therapeutics overvalued?
According to Wall Street analysts VYNE Therapeutics’s price is currently Undervalued.
Does VYNE Therapeutics pay dividends?
VYNE Therapeutics does not currently pay dividends.
What is VYNE Therapeutics’s EPS estimate?
VYNE Therapeutics’s EPS estimate is -$0.24.
How many shares outstanding does VYNE Therapeutics have?
VYNE Therapeutics has 14,098,888 shares outstanding.
What happened to VYNE Therapeutics’s price movement after its last earnings report?
VYNE Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.5. Following the earnings report the stock price went down -4.292%.
Which hedge fund is a major shareholder of VYNE Therapeutics?
Among the largest hedge funds holding VYNE Therapeutics’s share is Perceptive Advisors LLC. It holds VYNE Therapeutics’s shares valued at N/A.
---
VYNE Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.88 (159.03% Upside)
$5.88 (159.03% Upside)
Hedge Fund Trend
Decreased
By 121.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.08%
12-Months-Change
Fundamentals
Return on Equity
-46.40%
Trailing 12-Months
Asset Growth
139.67%
Trailing 12-Months
Company Description
VYNE Therapeutics
Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded in October, 2011 and is headquartered in Redwood City, CA.
---
VYNE Stock 12 Months Forecast
Average Price Target
$5.88
▲(159.03% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Bausch Health Companies
―
Syndax Pharmaceuticals
―
Kala Pharmaceuticals
―
Best Analysts Covering VYNE
1 Year
1 Year Success Rate
2/10 ratings generated profit
1 Year Average Return
-31.48%
reiterated a buy rating 2 months ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -31.48% per trade.
---